Chances dim for fiscal `97 boost in AIDS drug funds. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Chances dim for fiscal `97 boost in AIDS drug funds. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

AIDS Policy Law. 1997 Jun 13;12(11):1, 10. Unique Identifier : AIDSLINE MED/97702672

Abstract: Congressional leaders rejected a proposal to supplement Federal funding for State-run AIDS drug assistance programs (ADAP), and President Clinton refused to intervene. A proposal by Rep. Nancy Pelosi (D-CA) that included $68 million in additional ADAP funding was part of a supplemental appropriations bill aimed largely at paying for flood relief. Some State ADAP programs remain financially sound following the latest round of Ryan White CARE Act grant allocations. Several States have curtailed new enrollments or adopted other cost-saving measures. Almost all of the States' budgets are being rapidly depleted as more people demand access to expensive medicines. The worst problem is in Mississippi, where State funds are not used to cover AIDS programs. AIDS policy advocates and State public health officials were disappointed that President Clinton declined to support Rep. Pelosi's request. The President's AIDS policy director, Sandra Thurman, explained that the funding request could not be developed without taking into account two factors. First, the Department of Health and Human Services is seeking ways to extend Medicaid eligibility to more low-income people living with HIV, reducing the ADAP budget. Second, upcoming treatment guidelines could affect the amount of funding needed to adequately fund the ADAPs. The guidelines are expected to recommend combination drug therapy using a protease inhibitor.

Keywords: *Acquired Immunodeficiency Syndrome/DRUG THERAPY *Drug Therapy/ECONOMICS *Financing, Government *Medical Assistance
971030
M97A1308

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .